Towards a New Logic for Front End Management: From Drug Discovery to Drug Design in Pharmaceutical R&D

Creativity and Innovation Management

Volumn 16, Issue 2, 2007, Pages 106-120

  Elmquist, Maria ^a   Segrestin, Blanche ^b  

^a CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^b PSL RESEARCH UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862631449     PISSN: 09631690     EISSN: 14678691     Source Type: Journal    
DOI: 10.1111/j.1467-8691.2007.00424.x     Document Type: Article

References (57)

1. Adler, N., Shani, R. and Styhre, A. (2003) Collaborative Research in Organizations, Foundations for Learning, Change and Theoretical Development. Sage Publications, New York.
2. Argyris, C. (1993) Knowledge for Action: A Guide to Overcoming Barriers to Organizational Change. Jossey-Bass, San Francisco.
3. Argryis, C., Putnam, R. and Smith, D.M. (1995) Action Science – Concepts, Methods and Skills for Research and Intervention. Jossey-Bass, San Francisco.
4. Arora, A. and Gambardella, A. (1990) ‘Complementarity and External Linkages: the Strategies of the Large Firms in Biotechnology’, Journal of Industrial Economics, 38, 369–80.
5. Börjesson, S., Dahlsten, F. and Williander, M. (2006) ‘Innovative Scanning Experiences from an Idea Generation Project at Volvo Cars’, Technovation, 26, 775–83.
6. Burchill, G. and Fine, C.H. (1997) ‘Time Versus Market Orientation in Product Concept Development: Empirically-based Theory Generation’, Management Science, 43, 465–78.
7. Carbone, J. (2003) ‘Ethics, Patents and the Sustainability of the Biotech Business Model’, Journal of Law Computers & Technology, 17, 203–18.
8. Cheng, Y-T. and Van de Ven, A.H. (1996) ‘Learning the Innovation Journey: Order Out of Chaos’, Organization Science, 7, 593–614.
9. Colarelli O'Connor, G. and Rice, M.P. (2001) ‘Opportunity Recognition and Breakthrough Innovation in Large Established Firms’, California Management Review, 43, 95–116.
10. Cooper, R.G. (1997a) ‘Fixing the Fuzzy Front End of the New Product Process’, CMA Magazine, 71, 21–23.
11. Cooper, R.G. (1997b) ‘Taking the Fuzziness out of the Fuzzy Front End’, Research Technology Management, 42, 25–31.
12. Cooper, R.G. (1988) ‘The New Product Process: A Decision Guide for Management’, Journal of Marketing Management, 3, 238–55.
13. David, A. (2002) ‘Intervention Methodologies in Management Research’, paper presented at the EURAM Conference 9–11 May, Stockholm, Sweden.
14. DiMasi, J.A., Hansen, R.W. and Grabowski, H.G. (1991) ‘Cost of Innovation in the Pharmaceutical Industry’, Journal of Health Economics, 10, 107–42.
15. DiMasi, J.A., Hansen, R.W. and Grabowski, H.G. (2003) ‘The Price of Innovation: New Estimates of Drug Development Costs’, Journal of Health Economics, 22, 151–85.
16. Drews, J. (2000) ‘Drug Discovery: A Historical Perspective’, Science, 287, 1960.
17. Drucker, P.F. (1988) ‘The Coming of the New Organization’, Harvard Business Review, 66, 45–53.
18. Dubois, A. and Gadde, L.E. (2002) ‘Systematic Combining: An Abductive Approach to Case Research’, Journal of Business Research, 55, 553–60.
19. Federsel, H.-J. (2000) ‘Building Bridges from Process R&D: From a Customer–Supplier Relationship to Full Partnership’, Pharmaceutical Science Technology Today, 3, 265–72.
20. Gambardella, A. (1995) Science and Innovation, the US Pharmaceutical Industry during the 1980s, Cambridge University Press, Cambridge.
21. Gaudillière, J.-P. (2004) ‘Hormones, régimes d'innovation et stratégies d'entreprise: les exemples de Schering et Bayer’, Entreprises et Histoire, 36, 84–102.
22. Grabowski, H.G. and Vernon, J. (2000) ‘The Distribution of Sales Revenues from Pharmaceutical Innovation’, PharmacoEconomics, 18, 21–23.
23. Griffin, A. (1997) ‘The Effect of Project and Process Characteristics on Product Development Cycle Time’, Journal of Marketing Research, 34, 24–35.
24. Hatchuel, A. (2002) ‘Towards Design Theory and Expandable Rationality: The Unfinished Program of Herbert Simon’, Journal of Management and Governance, 5, 260–71.
25. Hatchuel, A. and Weil, B. (2001) ‘A New Approach of Innovative Design: An Introduction to C-K Theory’, in Proceedings of 14th International Conference on Engineering Design (ICED'03), Stockholm, Sweden, pp. 1794–1805.
26. Hatchuel, A., Le Masson, P. and Weil, B. (2004) ‘C-K Theory in Practice: Lessons from Industrial Applications’, in Proceedings of the 8th International Design Conference, Dubrovnik, pp. 245–57.
27. Hatchuel, A., Le Masson, P. and Weil, B. (2005) ‘The Development of Science-based Products: Managing by Design Spaces’, Creativity and Innovation Management, 14, 345–54.
28. Iansiti, M. and West, J. (1997) ‘Technology Integration: Turning Great Research into Great Products’, Harvard Business Review, 75, 69–79.
29. Kazakci, A.O. and Tsoukias, A. (2005) ‘The C-K Design Theory: A Theoretical Background for Personal Design Assistants’, Journal of Engineering Design, 16, 399–411.
30. Khurana, A. and Rosenthal, S.R. (1997) ‘Integrating the Fuzzy Front End of New Product Development’, Sloan Management Review, 38, 103–20.
31. Khurana, A. and Rosenthal, S.R. (1998) ‘Towards Holistic “Front Ends” in New Product Development’, Journal of Product Innovation Management, 15, 57–74.
32. Kim, J. and Wilemon, D. (2002) ‘Focusing the Fuzzy Front End in New Product Development’, R&D Management, 32, 269–79.
33. Kline, S.J. and Rosenberg, N. (1986) An Overview of Innovation. In: Landau, R. and Rosenberg, N. (eds.), The Positive Sum Strategy, National Academy Press, Washington, DC.
34. Koen, P., Ajamian, G., Burkhart, R., Clamen, A., Davidson, J., D'Amore, R., Elkins, C., Herald, K., Incorvia, M., Johnson, A., Karol, R., Seibert, R., Slavejkov, A. and Wagner, K. (2001) ‘Providing Clarity and a Common Language to the “Fuzzy Front End”’, Research Technology Management, March–April, 46–55.
35. Le Masson, P., Hatchuel, A. and Weil, B. (2006). Les processus d'innovation. Conception innovante et croissance des entreprises. Hermès, Paris.
36. Liebenau, J. (1987) Medical Science and Medical Industry, the Formation of the American Pharmaceutical Industry. The Macmillan Press, Baltimore, MD.
37. Lynn, G.S., Mazzuca, M., Morone, J.G. and Paulson, A. (1998) ‘Learning is the Critical Success Factor in Developing Truly New Products’, Research Technology Management, 41, 45–51.
38. Maidique, M.A. and Zirger, B.J. (1985) ‘The New Product Learning Cycle’, Research Policy, 14, 299–313.
39. Moulin, A.M. (1991) Le dernier langage de la médecine, P.U.F., Paris.
40. Nobelius, D. and Trygg, L. (2002) ‘Stop Chasing the Front End Process – Management of the Early Phases in Product Development Projects’, International Journal of Project Management, 20, 331–40.
41. Reinertsen, D.G. (1999) ‘Taking the Fuzziness out of the Fuzzy Front End’, Research Technology Management, November–December, 25–31.
42. Reinertsen, D.G. and Smith, P.G. (1991) ‘The Strategist's Role in Shortening Product Development’, The Journal of Business Strategy, July/August, 18–22.
43. Rice, M.P., Kelley, D., Peters, L. and Colarelli O'Connor, G. (2001) ‘Radical Innovation: Triggering Initiation of Opportunity Recognition and Evaluation’, R&D Management, 31, 409–20.
44. Sanderson, S. and Uzumeri, M. (1995) ‘Managing Product Families: The Case of the Sony Walkman’, Research Policy, 24, 761–82.
45. Schmid, E.F. and Smith, D.A. (2002) ‘Should Scientific Innovation be Managed?’, Drug Discovery Today, 7, 941–5.
46. Seget, S. (2002) Pharmaceutical Innovation: An Analysis of Leading Companies and Strategies, Datamonitor PLC.
47. Simon, H.A. (1986) Decision Making and Problem Solving, Research Briefing. National Academy Press, Washington, DC.
48. Starkey, K. and Madan, P. (2001) ‘Bridging the Relevance Gap: Aligning Stakeholders in the Future of Management Research’, British Journal of Management, 12, 3–26.
49. Studt, T. and Casssidy, R. (1995) ‘The Realities of Drug Discovery, from an Insiders Viewpoint’, R&D Magazine, November, 58–60.
50. Sundgren, M. (2004) New Thinking, Management Control and Instrumental Rationality. Managing Organizational Creativity in Pharmaceutical R&D. PhD thesis, Department for Project Management, Chalmers University of Technology, Gothenburg.
51. Tapon, F. and Cadsby, C.B. (1996) ‘The Optimal Organization of Research: Evidence from Eight Case Studies of Pharmaceutical Firms’, Journal of Economic Behavior & Organization, 31, 381–99.
52. Thomke, S. (2001) ‘Enlightened Experimentation – The New Imperative for Innovation’, Harvard Business Review, February, 67–76.
53. Thomke, S., Von Hippel, E. and Franke, R. (1998) ‘Modes of Experimentation: An Innovation Process – and Competitive – Variable’, Research Policy, 27, 315–32.
54. Van de Ven, A.H. (1986) ‘Central Problem in the Management of Innovation’, Management Science, 32, 590–607.
55. Verganti, R. (1999) ‘Planned Flexibility: Linking Anticipation and Reaction in Product Development Projects’, Journal of Product Innovation Management, 16, 363–76.
56. Walsh, V. (1984) ‘Invention and Innovation in the Chemical Industry: Demand-pull or Discovery-push?’, Research Policy, 13, 211–34.
57. Zucker, L.G. and Darby, M.R. (1997) ‘Present at the Biotechnological Revolution: Transformation of Technological Identity for a Large Incumbent Pharmaceutical Firm’, Research Policy, 26,429–46.